Format

Send to

Choose Destination
J Invest Dermatol. 2011 Sep;131(9):1817-20. doi: 10.1038/jid.2011.147. Epub 2011 May 19.

Mechanisms of resistance to RAF inhibitors in melanoma.

Author information

1
Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA. Andrew.Aplin@KimmelCancerCenter.Org

Abstract

The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has been lauded as a success story for personalized cancer therapy since short-term clinical responses were observed in the majority of patients. However, initial responses were followed by subsequent tumor re-growth, and a subset of patients showed intrinsic resistance. Bi-directional translational efforts are now essential to determine the mechanisms underlying acquired/secondary and intrinsic resistance to RAF inhibitors.

PMID:
21593776
PMCID:
PMC3156870
DOI:
10.1038/jid.2011.147
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center